Skip to main content

Explore our strategy and projects
to learn about the future of our company

Results FY 2022 (€/MLN)

1,361

Revenues

514

Adjusted EBITDA

319

Adjusted net profit

316

Free cash flow

Stock price

Discover more

Press releases

25/01/24 - 7:48

Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023
Learn More

Presentations

15/12/23

Diasorin Investor Day 2023 Presentation
Learn More
Calendar

Calendar

Jefferies - London Healthcare Conference

London

IR

View all

2023 Investor Day: Diasorin 3.0

On December 15, 2023 Diasorin Management Team presented the new Business Plan.

Discover more
investors Day

Keep
in touch

Sign up for our investor alerts
and stay informed
on the latest developments

Privacy Statement *
The Undersigned Confirms That The Information. Provided Pursuant To Leg. Decree No. 196/2003 Has Been Read And Accepted.